A Phase 1 Window of Opportunity Study Investigating the Pharmacodynamic Biomarker Effects of AZD2014 (an mTOR1/2 Inhibitor) Given Prior to Radical Prostatectomy

Trial Profile

A Phase 1 Window of Opportunity Study Investigating the Pharmacodynamic Biomarker Effects of AZD2014 (an mTOR1/2 Inhibitor) Given Prior to Radical Prostatectomy

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Feb 2017

At a glance

  • Drugs Vistusertib (Primary)
  • Indications Prostate cancer
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Feb 2017 Results analysing pharmacodynamic biomarker effects of vistusertib given prior to radical prostatectomy and safety presented at the 2017 Genitourinary Cancers Symposium.
    • 06 Jan 2017 Planned number of patients changed from 20 to 23.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top